Aravive to Present Updated Modeling Data from Batiraxcept Clinical Trials at the AACR Annual Meeting

Rhea-AI Summary

Aravive, Inc. (Nasdaq: ARAV) plans to present updated exposure-response analyses from its Phase 1b trials for platinum-resistant ovarian cancer and clear cell renal cancer at the AACR annual meeting from April 8-13, 2022. The presentation, titled "Exposure-Response Analysis of Batiraxcept and Application to Recommended Phase 2 Dose in Platinum-Resistant Ovarian and Clear Cell Renal Cancers," will be delivered virtually on April 8, 2022. Batiraxcept, an ultra-high affinity decoy protein, targets metastatic disease and has received Fast Track Designation from the FDA.

Positive

• Presentation of pivotal trial data at AACR meeting.
• Batiraxcept has received Fast Track Designation by the FDA.
• Active Phase 3 trial in platinum-resistant ovarian cancer.

Negative

• None.

HOUSTON, March 02, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, will present updated exposure-response analyses from the Phase 1b platinum-resistant ovarian cancer and Phase 1b clear cell renal cancer trials at the American Association for Cancer Research (AACR) annual meeting taking place between April 8-13, 2022 in New Orleans, Louisiana. The abstract presentation at AACR will be presented virtually.

Presentation Details
Title: Exposure-Response Analysis of Batiraxcept and Application to Recommended Phase 2 Dose in Platinum-Resistant Ovarian and Clear Cell Renal Cancers
Abstract Number: 7867
Presentation Type: Remote Poster Presentation
Date: April 8, 2022

About Aravive
Aravive, Inc. is a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease. Our lead product candidate, batiraxcept (formerly AVB-500), is an ultra-high affinity decoy protein that binds to GAS6, the sole ligand that activates AXL, thereby inhibiting metastasis and tumor growth, and restoring sensitivity to anti-cancer agents. Batiraxcept has been granted Fast Track Designation by the U.S. FDA and Orphan Drug Designation by the European Commission in platinum-resistant recurrent ovarian cancer. Batiraxcept is in an active registrational Phase 3 trial in platinum resistant ovarian cancer (NCT04729608), a Phase 1b/2 trial in clear cell renal cell carcinoma (NCT04300140), and a Phase 1b/2 trial in pancreatic adenocarcinoma (NCT04983407). Additional information at www.aravive.com.

Contact:
Marek Ciszewski, J.D.
Vice President, Investor Relations
marek@aravive.com
(562) 373-5787

FAQ

What is Aravive's recent presentation about at the AACR annual meeting?

Aravive will present updated exposure-response analyses from its Phase 1b trials for platinum-resistant ovarian cancer and clear cell renal cancer.

When will Aravive present its findings at AACR?

The presentation is scheduled for April 8, 2022.

What is batiraxcept and its relevance in cancer treatment?

Batiraxcept is an ultra-high affinity decoy protein that inhibits metastasis and tumor growth, with potential applications in platinum-resistant ovarian and clear cell renal cancers.

What designations has batiraxcept received?

Batiraxcept has received Fast Track Designation from the FDA and Orphan Drug Designation from the European Commission.

What trials is Aravive currently conducting with batiraxcept?

Aravive has an active Phase 3 trial in platinum-resistant ovarian cancer and Phase 1b/2 trials in clear cell renal cell carcinoma and pancreatic adenocarcinoma.